Nuvation Bio NUVB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -105%+5,658pp | -338.7%+7,189pp | -871%+25,009pp | -1,564.9%+35,909pp | -5,762.8%— | |
| Net margin | -102.1%+5,432pp | -325.3%+6,888pp | -813.1%+23,807pp | -1,413.4%+34,177pp | -5,534.2%— | |
| EBITDA margin | -103.6%+5,651pp | -336%+7,183pp | -865.7%+24,990pp | -1,557.6%+35,888pp | -5,754.3%— | |
| Free cash flow margin | -93.5%+1,343pp | -288.4%+1,368pp | -740.2%+3,846pp | -1,173.2%+4,699pp | -1,436.4%— | |
| Returns | ||||||
| Return on equity | -39.5%+80.2pp | -53.2%+53.1pp | -52.5%+43.0pp | -64.4%+51.4pp | -119.7%-109pp | |
| Return on assets | -26.5%+83.2pp | -36%+61.7pp | -37.1%+51.5pp | -32.7%+50.0pp | -109.7%-98.8pp | |
| Return on invested capital | -47.4%+86.1pp | -67%+51.1pp | -60.6%+43.4pp | -106.9%+24.9pp | -133.5%-118pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.2× | 0.1×+0.1× | 0×0.0× | 0×0.0× | 0×— | |
| Liquidity | ||||||
| Current ratio | 7.4×-1.6× | 7×-2.1× | 8.5×-1.1× | 9.4×-2.1× | 9×-29.6× | |
| Quick ratio | 7.2×-1.8× | 6.8×-2.2× | 8.4×-1.2× | 9.4×-2.1× | 9×-29.6× | |
| Cash ratio | 1.6×+0.7× | 2×+1.4× | 1.5×+0.9× | 3.7×+3.1× | 0.9×-1.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.2× | 0.2×+0.2× | 0.2×+0.2× | 0.2×+0.1× | 0×0.0× | |
| Debt-to-assets | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0×0.0× | |
| Interest coverage | -7.4×+1,591× | -15.6×+1,722× | -32.8×+2,187× | -328.4×+3,745× | -1,598.6×— | |
| Per Share | ||||||
| Book value per share | $0.85-31.7% | $0.90-48.1% | $0.95-48.2% | $1.09+4.1% | $1.24-54.3% | |
| Valuation | ||||||
| Market capitalization | $1.49B+150% | $3.07B+243% | $1.27B+126% | $697.54M+9.1% | $596.07M-25.2% | |
| Enterprise value | $1.42B+154% | $2.97B+241% | $1.23B+126% | $507.33M-18.2% | $559.51M-27.0% | |
| Price / sales | 10.4×-44.0× | 48.8×-64.9× | 47.3×-212× | 48.6×-397× | 54.4×— | |
| Price / book | 4.7×+3.2× | 10×+8.1× | 3.9×+2.8× | 1.9×-0.6× | 1.4×+0.1× | |
| EV / sales | 9.9×-41.1× | 47.1×-63.2× | 45.8×-205× | 35.3×-397× | 51.1×— | |
| Free cash flow yield | -9%+17.4pp | -5.9%+8.7pp | -15.6%+2.1pp | -24.1%-11.0pp | -26.4%-18.3pp | |
| Earnings yield | -9.8%+91.9pp | -6.7%+56.8pp | -17.2%+77.8pp | -29.1%+50.8pp | -101.7%-93.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nuvation Bio's profit margins?
- Nuvation Bio (NUVB) runs a 54.3% gross margin and a -105.0% operating margin, with a -102.1% net margin.
- Where do Nuvation Bio's ratios come from?
- Every ratio is computed from Nuvation Bio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.